Latest News

Piramal Imaging Announces Strategic Partnership with PET Pharm Biotech for Exclusive Commercialization of NeuraCeq(TM) in Taiwan

媒體:PR Newswire

BERLIN and BOSTON, Sept. 6, 2016 /PRNewswire/ -- Piramal Imaging SA and PET Pharm Biotech Co. Ltd today announce the companies have entered into a strategic partnership and licensing agreement to provide PET Pharm Biotech with exclusive rights to manufacture, market, and distribute NeuraCeq (florbetaben F18 injection), throughout Taiwan. NeuraCeq is a radiopharmaceutical tracer for Positron Emission Tomography (PET) imaging of patients being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment....

https://www.perssupport.nl/persbericht/101396/piramal-imaging- announces-strategic-partnership- with-pet- pharm-biotech- for-exclusive- commercialization-of-neuraceq- tm-in- taiwan

Read More

士宣製造阿茲海默診斷新藥 可望在台上市

媒體:經濟日報

士宣生技今(6)日宣布,該公司與國際大藥廠Piramal Imaging SA簽訂了策略合作夥伴關係和獨家授權協議,Piramal Imaging將提供士宣生技在台灣製造、運銷阿茲海默症診斷新藥NeuraCeq(Florbetaben F-18注射液)的權利。

士宣表示,NeuraCeq使用於正子斷層掃描(PET)中作為示蹤劑,當患者被評估可能為阿茲海默症或有其他會導致認知障礙的疾病時,即可利用此方法進行進一步診斷。NeuraCeq已分別取得美國、歐盟、韓國的上市許可,而士宣生技目前正展開申請此新藥在台上市的許可程序。

http://udn.com/news/story/6/1944002

Read More